July 22, 2014 10:22 PM ET

Biotechnology

Company Overview of aTyr Pharma Inc.

Company Overview

aTyr Pharma Inc., a protein therapeutics company, engages in the discovery and development of biologic therapeutics based on physiocrines. It focuses on the discovery of phyisiocrines, which are a class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in various physiologic settings; and the development of physiocrine-based medicines for indications in the areas of hematology, immune modulation, infection, and metabolism. The company’s lead product is Tmax, which is in preclinical development for thrombocytopenia. aTyr Pharma Inc. was incorporated in 2005 and is based in San Diego, California.

3565 General Atomics Court

Suite 103

San Diego, CA 92121

United States

Founded in 2005

Phone:

858-731-8389

Fax:

858-731-8394

Key Executives for aTyr Pharma Inc.

Executive Chairman and Chief Executive Officer
Age: 54
President and Chief Operating Officer
Founder and Director
Age: 73
Chief Medical Officer
Associate Director of Discovery Research
Compensation as of Fiscal Year 2014.

aTyr Pharma Inc. Key Developments

aTyr Pharma Inc. Presents at Boston CEO Conference, Jun-04-2014

aTyr Pharma Inc. Presents at Boston CEO Conference, Jun-04-2014. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Presentation Date & Speakers: Jun-04-2014, John D. Mendlein, Executive Chairman and Chief Executive Officer.

aTyr Pharma Completes First Phase 1 Study for Rare Disease Program

aTyr Pharma announced completion of Phase 1 for its lead program, Resokine IV, which marked the first ever administration of a Physiocrine to humans, was conducted in healthy male and female subjects in the European Union to assess the safety and tolerability of Resokine IV. aTyr Pharma is developing Resokine IV as a potential therapeutic for rare immune disorders. This study advances a range of therapeutic programs to treat rare immune-imbalanced diseases and develop a rare disease pipeline in immunology. The Phase 1 study was a double blinded, placebo-controlled, trial demonstrating that Resokine IV was well tolerated and safe at all doses tested. No serious adverse effects were observed. The data from 32 healthy subjects in four dose cohorts supports the basic premise of Resokine IV as an immuno-modulator rather than a classic interleukin or interferon with systemic immuno-stimulating properties upon administration.

aTyr Pharma Appoints Biotech Pioneer, Dr. Ed Penhoet, to Board of Directors

aTyr Pharma (aTyr) announced the appointment of Ed Penhoet, Ph.D., to the company's board of directors (BOD). Dr. Penhoet, who co-founded Chiron, is an accomplished scientist and biotech pioneer. He has served on the Independent Citizens Oversight Committee (ICOC) for the California Institute of Regenerative Medicine (CIRM) and was recently appointed to President Obama's Council of Advisors on Science and Technology (PCAST). On aTyr's BOD, Dr. Penhoet will represent Alta Partners, an aTyr investor.

Similar Private Companies By Industry

Company Name Region
Fidopharm, Inc. United States
Invent Pharmaceuticals, Inc. United States
Expression Genetics, Inc. United States
EXO LLC United States
Oldtech, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 29, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact aTyr Pharma Inc., please visit www.atyrpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.